DNA repair is an essential cellular process mediating response to DNA replication errors, endogenous and exogenous DNA damage, and cell survival. Despite the importance of DNA repair, there has been little analysis of the role of many DNA repair processes in maintenance of the stem cell phenotype as functionally measured in terms of stem cell longevity, long term repopulating capacity after transplantation, and multilineage hematopoietic and lymphoid reconstitution after DNA damage. In this proposal, the investigators will use murine models of DNA repair defects to focus on hematopoietic stem cell repair of methylating agent induced DNA damage. Therapeutic methylating agents cause dose-limiting myelosuppression and are implicated in treatment-related leukemias in humans. Thus, these agents induce DNA damage that is both cytotoxic and mutagenic to hematopoietic stem cells. Two important components of methyl DNA adduct repair are mismatch repair [MMR] and 06-alkylguanine-DNA alkyltransferase [AGT], encoded by the MGMT gene. The investigators have previously shown the importance of MMR and MGMT in preventing the induction of methylating agent induced lymphomas in the mouse. Furthermore, defects in MMR and MGMT have been seen in human leukemias and lymphomas. No studies have examined the impact of DNA repair defects on stem cell function and malignant transformation. Using mice defective in the DNA repair processes of MMR and/or MGMT, the specific aims of this proposal are to: (1) determine whether DNA repair capacity for methylating adducts (i.e., MMR and MGMT) affect key hematopoietic stem cell functions. These characteristics include myeloid and lymphoid proliferation and differentiation, cell cycle distribution and quiescence, long-term repopulating cell survival and longevity, and sequential transplant capacity; (2) determine whether defects in DNA repair affect the competitive long-term repopulation capacity of stem cells exposed to methylating agents; and (3) determine whether the therapeutic methylating agent-induced malignant transformation potential of transplanted stem cells is affected by defects in DNA repair, and whether this mimics treatment-related leukemias in humans. These studies will impact our appreciation of the role of DNA repair in human hematologic malignancies and in the maintenance of human stem cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA063193-07
Application #
6512962
Study Section
Chemical Pathology Study Section (CPA)
Program Officer
Okano, Paul
Project Start
1994-05-01
Project End
2006-02-28
Budget Start
2002-03-01
Budget End
2003-02-28
Support Year
7
Fiscal Year
2002
Total Cost
$267,750
Indirect Cost
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Qing, Yulan; Wang, Zhengqi; Bunting, Kevin D et al. (2014) Bcl2 overexpression rescues the hematopoietic stem cell defects in Ku70-deficient mice by restoration of quiescence. Blood 123:1002-11
Desai, Amar; Webb, Bryan; Gerson, Stanton L (2014) CD133+ cells contribute to radioresistance via altered regulation of DNA repair genes in human lung cancer cells. Radiother Oncol 110:538-45
Qing, Yulan; Lin, Yuan; Gerson, Stanton L (2012) An intrinsic BM hematopoietic niche occupancy defect of HSC in scid mice facilitates exogenous HSC engraftment. Blood 119:1768-71
Kisby, G E; Olivas, A; Park, T et al. (2009) DNA repair modulates the vulnerability of the developing brain to alkylating agents. DNA Repair (Amst) 8:400-12
Liu, Lili; Gerson, Stanton L (2006) Targeted modulation of MGMT: clinical implications. Clin Cancer Res 12:328-31
Vollweiler, J L; Zielske, S P; Reese, J S et al. (2003) Hematopoietic stem cell gene therapy: progress toward therapeutic targets. Bone Marrow Transplant 32:1-7
Reese, Jane S; Liu, Lili; Gerson, Stanton L (2003) Repopulating defect of mismatch repair-deficient hematopoietic stem cells. Blood 102:1626-33
Bowman, Janice E; Reese, Jane S; Lingas, Karen T et al. (2003) Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients. Mol Ther 8:42-50
Gerson, Stanton L (2002) Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20:2388-99
Zhou, Hang; Liu, Lili; Lee, Keunmyoung et al. (2002) Lung tumorigenesis associated with erb-B-2 and erb-B-3 overexpression in human erb-B-3 transgenic mice is enhanced by methylnitrosourea. Oncogene 21:8732-40

Showing the most recent 10 out of 39 publications